[Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]

Translated title of the contribution: [Autom. eng. transl.] [Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]

Antonio Gasbarrini, Vincenzo Palmieri, Salvatore D'Angelo, Domenico Germano, Teresa Zolfino, Domenico Sansonno, Lydia Giannitrapani, Antonio Benedetti, Vincenzo Montesarchio, Adolfo Attili, Angela Buonadonna, Sandro Barni, Michela E. Burlone, Umberto Cillo, Simona Marenco, Erica Villa, Petros Giovanis, Ilaria Proserpio, Carlo Saitta, Giulia MaginiRita Cengarle, Giammarco Fava, Filiana Cuttone, Nicola Calvani, Mario Angelico, Francesco Di Costanzo, Alfonso Noto, Guido Poggi, Massimo Marignani, Stefano Cascinu, Domenico Amoroso, Elena Massa, Lory Saveria Crocè, Antonio Picardi, Salvatore Tumulo, Claudia Erminero, Riccardo Lencioni, Vito Lorusso

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Sorafenib, an oral multikinase inhibitor, is the only targeted agent approved for the treatment of patients with hepatocellular carcinoma (HCC) after demonstration to increase overall survival compared to placebo in two randomized phase III study. GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) is the largest, global, non-interventional, prospective study of patients with uHCC (n>3200) treated with sorafenib in real-life clinical practice conditions. Here we report the final analysis of safety and efficacy in the Italian cohort of patients.
Translated title of the contribution[Autom. eng. transl.] [Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]
Original languageItalian
Pages (from-to)217-226
Number of pages10
JournalRECENTI PROGRESSI IN MEDICINA
Volume106
DOIs
Publication statusPublished - 2015

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents
  • Carcinoma, Hepatocellular
  • Female
  • Humans
  • Italy
  • Liver Neoplasms
  • Male
  • Middle Aged
  • Niacinamide
  • Phenylurea Compounds
  • Prospective Studies

Fingerprint

Dive into the research topics of '[Autom. eng. transl.] [Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy]'. Together they form a unique fingerprint.

Cite this